OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Tawbi on the Efficacy of Relatlimab/Nivolumab in Advanced Melanoma

June 6th 2021

Hussein A. Tawbi, MD, PhD, discusses the efficacy of relatlimab plus nivolumab in patients with advanced melanoma.

Dr. Skoulidis on the Results of Subgroup Analyses of the CodeBreaK 100 Trial in KRAS G12C-Mutant NSCLC

June 4th 2021

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the results of subgroup analysis from the phase 2 CodeBreaK 100 trial in patients with KRAS G12C-mutant non–small cell lung cancer.

Dr. Reck on Updated Results of the CheckMate 9LA Trial in Advanced NSCLC

June 4th 2021

Martin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.

Dr. Choueiri on the Efficacy of Post-Nephrectomy, Adjuvant Pembrolizumab in RCC

June 4th 2021

Toni K. Choueiri, MD, discusses the efficacy of pembrolizumab as a post-nephrectomy adjuvant therapy for patients with renal cell carcinoma from the phase 3 KEYNOTE-564 trial.

Dr. Abedin on the Need for Risk Stratification Before Chemoimmunotherapy in CLL

June 3rd 2021

Sameem Abedin, MD, discusses the need for risk stratification prior to giving chemoimmunotherapy to patients with chronic lymphocytic leukemia.

Dr. Powell on Remaining Questions With Interstitial Lung Disease in HER2+ Breast Cancer

June 3rd 2021

Charles Powell, MD, MBA, discusses remaining questions with interstitial lung disease in HER2-positive breast cancer.

Dr. Shah on Shortcomings With BTK Inhibitors in High-Risk MCL

June 3rd 2021

Bijal Shah, MD, MS, discusses shortcomings with BTK inhibitors in high-risk mantle cell lymphoma.

Dr. Davies on Key Considerations for Early-Relapse Multiple Myeloma

June 3rd 2021

Faith Davies, MD, discusses key considerations for developing a treatment strategy for patients with early-relapse multiple myeloma.

Dr. Burgess on Improving Biomarkers for PARP Inhibitors in Prostate Cancer

June 2nd 2021

Earle Burgess, MD, discusses the need for improved biomarkers for PARP inhibitors in prostate cancer.

Dr. Lilenbaum on the Clinical Implications of the FDA Approval of Lurbinectedin in SCLC

June 2nd 2021

Rogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.

Dr. Hammers on the Potential Utility of HIF-2α Inhibitors in RCC

June 2nd 2021

Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.

Dr. Lower on the Importance of Tucatinib Plus Capecitabine/Trastuzumab in HER2+ Breast Cancer

June 2nd 2021

Elyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.

Dr. Yacoub on Next Steps With Parsaclisib Plus Ruxolitinib in Myelofibrosis

June 1st 2021

Abdulraheem Yacoub, MD, discusses next steps with the combination of parsaclisib and ruxolitinib in myelofibrosis.

Dr. Choti on Pursuing Chemotherapy Following Tumor Resection in Advanced CRC

June 1st 2021

Michael A. Choti, MD, discusses pursuing chemotherapy following tumor resection in advanced colorectal cancer.

Dr. Ross on Toxicity Concerns With Combination Therapies in EGFR+ NSCLC

June 1st 2021

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

Dr. Ghosh on the Role of Ide-Cel in Relapsed/Refractory Multiple Myeloma

June 1st 2021

Monalisa Ghosh, MD, discusses the role of idecabtagene vicleucel in relapsed/refractory multiple myeloma landscape.

Dr. Javle on the FDA Approval of Infigratinib in FGFR-Mutated Cholangiocarcinoma

May 28th 2021

Milind Javle, MD, discusses the FDA approval of infigratinib in FGFR-mutated cholangiocarcinoma.

Dr. Morgan on Optimizing Treatment in Ultra High–Risk Multiple Myeloma

May 27th 2021

Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.

Dr. Socinski on the Utility of ctDNA Testing in Lung Cancer

May 26th 2021

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

Dr. Doroshow on Increasing Patient Accrual to Clinical Trials During the COVID-19 Pandemic

May 26th 2021

James H. Doroshow, MD, discusses strategies that were implemented to increase patient accrual to clinical trials during the COVID-19 pandemic.